Mucosal-associated invariant T (MAIT) cells are an evolutionarily conserved ([@bib53]; [@bib23]) innate-like population of T cells that are very abundant in humans ([@bib44]; [@bib53]; [@bib45]). MAIT cells have been implicated in protective and aberrant immunity, but their specific function remains obscure ([@bib25]; [@bib7]; [@bib43]; [@bib15]; [@bib17]; [@bib29]; [@bib38]; [@bib5]; [@bib12]; [@bib16]; [@bib37]; [@bib2]; [@bib50]). Once activated via their αβ TCR, MAIT cells rapidly secrete an array of cytokines ([@bib27]; [@bib11]; [@bib52]). Unlike the classical MHC-restricted T lymphocytes, MAIT cells typically express an invariant TCR α-chain paired with one of a selected group of TCR β-chains, with the MAIT TCR being highly conserved across mammals ([@bib53]; [@bib23]). In humans, the TCR α-chain comprises the TRAV1-2 gene that combines with the TRAJ33 gene segment, with limited nonnucleotide (N) additions/deletions at the TRAV1-2-TRAJ33 junction. In mice, the MAIT TCR repertoire uses the orthologous TCR α-chain (TRAV1-TRAJ33). In addition, the human MAIT TCR α-chain repertoire also includes smaller subsets containing TRAJ20 and TRAJ12 gene segments paired with the TRAV1-2 gene ([@bib46]). Although the human MAIT TCR β-chain repertoire was considered to mainly be comprised of TRBV20, TRBV6-1, and TRBV6-4 genes ([@bib53]), MR1-tetramer based studies have demonstrated that the MAIT TCR β-chain repertoire is more diverse ([@bib46]). Moreover, the MAIT TCR β-chain is typified by a hypervariable complementarity-determining region (CDR) 3β loop ([@bib53]; [@bib46]). The semiinvariant nature of the MAIT TCR resonates with the repertoire diversity of type I NKT TCRs ([@bib3]; [@bib32]; [@bib41]; [@bib39]; [@bib48]). However, although we have a growing understanding of how the NKT TCR repertoire can interact with a range of CD1d-restricted, lipid-based Ags, the molecular basis of MAIT TCR α- and β-chain heterogeneity, CDR3β hypervariability, and MR1-ligand diversity on MAIT cell function is unknown.

The MAIT TCR is restricted by the MHC class I--related molecule MR1 ([@bib54]; [@bib21]; [@bib22]). MR1 is a monomorphic Ag-presenting molecule that is highly conserved across mammals ([@bib55]). Although the MR1 transcript is expressed widely ([@bib19]; [@bib47]), cell surface expression of MR1 is very low/absent, thereby indicating that other factors, including Ag supply, can determine the level of MR1 that egresses to the cell membrane ([@bib22]; [@bib4]). Recently, it has been established that MR1 can bind vitamin B--based precursors and derivatives that originate from folic acid (vitamin B9) and riboflavin (vitamin B2) biosynthesis ([@bib28]). Specifically, MR1 can present 6-formylpterin (6-FP), a naturally occurring photo-degradation product of folic acid, and a series of ribityllumazines, including 6,7-dimethyl-8-[d]{.smallcaps}-ribityllumazine (RL-6,7-DiMe), 6-methyl-7-hydroxy-8-[d]{.smallcaps}-ribityllumazine (RL-6-Me-7-OH; [@bib28]; [@bib40]), 5-(2-oxoethylideneamino)-6-[d]{.smallcaps}-ribitylaminouracil (5-OE-RU), and 5-(2-oxopropylideneamino)-6-[d]{.smallcaps}-ribitylaminouracil (5-OP-RU; [@bib6]). The MR1 Ag-binding cleft is ideally disposed to bind to these small organic metabolites, with the ligands being closely sequestered by an aromatic cradle within MR1, whereupon some of the ligands can form a covalent bond (Schiff base) with MR1 ([@bib28]). Although the 6-FP ligand up-regulated MR1 cell surface expression, it did not stimulate MAIT cells ([@bib28]). However, the ribityllumazines were stimulatory, with the extent of MAIT cell potency varying markedly, such that synthetic rRL-6-CH~2~OH (reduced 6-hydroxymethyl-8-[d]{.smallcaps}-ribityllumazine) is ∼1,000 times more potent than the weak agonists RL-6,7-DiMe and RL-6-Me-7-OH ([@bib28]). We recently traced the high potency of rRL-6-CH~2~OH to MR1 trapping and presentation of a relatively unstable pyrimidine-based transitory derivative (5-OP-RU), with similar high potency also found for a homologue with one carbon less (5-OE-RU) but no activity for another homologue with one extra carbon, 5-(1-methyl-2-oxopropylideneamino)-6-[d]{.smallcaps}-ribitylaminouracil (5-MOP-RU; [@bib6]). Thus, the MR1 cleft, although having a penchant for small molecule uracil derivatives, nonetheless has sufficient plasticity to accommodate a range of chemical entities, but the nature and relative impact of molecular determinants on MR1 function remains underexplored.

We recently provided insight into how the human TRAV1-2-TRAJ33-TRBV6-1^+^ MAIT TCR recognized human MR1 presenting 6-FP, RL-6-Me-7-OH ([@bib40]) and two short lived adducts, 5-OE-RU and 5-OP-RU, arising from reaction of glyoxal and methylglyoxal, respectively, with 5-amino-6-[d]{.smallcaps}-ribitylaminouracil (5-A-RU), an intermediate in bacterial riboflavin synthesis ([@bib6]). Regardless of the stimulatory properties of the ligand, the MAIT TCR docked in a conserved manner with MR1 ([@bib40]; [@bib6]), with this consensus docking mode being observed in a humanized bovine MR1-MAIT TCR ternary complex with undefined Ags bound ([@bib31]). The important role of the MAIT TCR α-chain was underpinned by the marked effect some residues had on MR1-Ag recognition. In contrast, the germline-encoded regions of the TCR β-chain appeared less ideally disposed to interact with MR1, which was consistent with an alanine-scanning mutagenesis study on the human MAIT TCR TRBV6-1 encoded region ([@bib45]). Nevertheless, the CDR3β loop interacted extensively with MR1, being situated directly above the Ag itself, thereby suggesting that CDR3β loop hypervariability may impact on MAIT TCR recognition in an Ag-dependent manner. MR1 tetramers loaded ([@bib46]) or refolded ([@bib6]) with the transitory intermediates stained the majority of MAIT cells, suggesting that MAIT cells, regardless of their MAIT TCR repertoire, are tailored to interact with potent Ags, in a manner analogous to how the CD1d-restricted ligand α-galactosylceramide represents the universal potent ligand for NKT cells ([@bib33]). However, it is unknown whether less potent MAIT cell Ags are recognized differentially on account of variations in the MAIT TCR repertoire, as observed in NKT cell recognition of weak agonists ([@bib41]; [@bib34]; [@bib59]).

In this study, we address the impact of MAIT TCR heterogeneity on recognition of different MR1-restricted ligands. Although the MAIT TCR heterogeneity converged onto a common docking footprint on MR1, we show that TCR β-chain usage can modulate MAIT TCR recognition and fine-tune the response in an Ag-dependent manner.

RESULTS
=======

A novel MAIT cell inhibitory ligand
-----------------------------------

We previously established that 6-FP could up-regulate MR1 cell surface expression on C1R.MR1 cells without activating MAIT cells or Jurkat cells transduced with a MAIT TCR (Jurkat.MAIT; [@bib28]). Instead, 6-FP was a weak competitive antagonist of MAIT cell activation ([@bib40]). Thus, we evaluated whether analogues of 6-FP could competitively inhibit MAIT cell recognition more potently. Although the compounds 6,7-dimethylpterin, 6-hydroxymethylpterin, pterin, [l]{.smallcaps}-monapterin, tetrahydrobiopterin, xanthopterin, and pterin-6-carboxylic acid ([Fig. 1 a](#fig1){ref-type="fig"}) could not be refolded with MR1 or increase MR1 cell surface expression, acetyl-6-FP (Ac-6-FP) readily refolded with MR1 as judged by gel filtration profile and cell staining with the MR1-reactive mAb 26.5 (not depicted). Analogous to MR1-6-FP tetramers, MR1--Ac-6-FP tetramers did not stain human PBMCs ([Fig. 1 b](#fig1){ref-type="fig"}), which is indicative of Ac-6-FP not representing a stimulating ligand for MAIT cells. Ac-6-FP differs from 6-FP by the presence of an acetyl group ([Fig. 1 a](#fig1){ref-type="fig"}), yet it still possesses a formyl group at the 6-position and thus was anticipated to form a Schiff base when bound to MR1. Ac-6-FP caused much greater surface up-regulation of MR1 when compared with 6-FP or other pterin-based compounds ([Fig. 1 c](#fig1){ref-type="fig"}). Interestingly, both ligands induced increased MR1 expression, but the up-regulation induced by 6-FP was slower and less pronounced than that caused by Ac-6-FP. Intriguingly, the effect of 6-FP was also transient, whereas it was maintained for at least 24 h with Ac-6-FP ([Fig. 1 d](#fig1){ref-type="fig"}). Ac-6-FP, although nonstimulatory for MAIT cells, nevertheless strongly inhibited Jurkat.MAIT activation in response to an agonist ligand, being a 100 fold more potent inhibitor than 6-FP in cell-based assays, in which CD69 up-regulation and IL-2 production were used as functional readouts ([Fig. 2, a and b](#fig2){ref-type="fig"}). To formally test the apparent stabilizing effect of Ac-6-FP, we undertook thermostability assays on the refolded MR1--Ag complex, and compared these values to the half maximum melting temperatures (Tm50) of recombinant MR1-6-FP, MR1--5-OP-RU, MR1-K43A-5-OP-RU, and MR1-K43A (empty; [Fig. 2 c](#fig2){ref-type="fig"}). The MR1-K43A protein, in which the Lys43 had been mutated to alanine to prevent Schiff base formation with any ligands ([@bib46]) was refolded in the absence of any ligands. This MR1-K43A empty molecule had a Tm50 of 40°C and served as the baseline to assess the impact of the effect of Schiff base formation and the presence of ligand on MR1 stability. Notably, although MR1-K43A-5-OP-RU exhibited a moderately increased stability (Tm50 46°C) to that of MR1-K43A, MR1--5-OP-RU had a markedly increased Tm50 value of 63°C. Thus, the ability of 5-OP-RU to form a Schiff base with MR1 resulted in a 17°C increase in MR1 stability. In contrast, the Tm50 of MR1-6-FP was 56°C, indicating that the stabilizing effect of the Schiff base formation is also dependent on the nature of the bound ligand. Interestingly, MR1--Ac-6-FP exhibited a Tm50 value of 64°C, suggesting that the presence of the acetyl group in Ac-6-FP led to an 8°C increase in stability compared with MR1-6-FP. The higher stability of MR1--Ac-6-FP was consistent with Ac-6-FP being a more potent inhibitor than 6-FP and having a prolonged effect on cell surface expression of MR1.

![**MR1 tetramer staining and MR1 up-regulation by 6-FP and Ac-6-FP.** (a) Chemical structures of MR1-restricted pterin ligands (6-FP \[6-FP, i\] and acetyl-6-FP \[Ac-6-FP, ii\]) and pterin-based compounds that did not bind to MR1 (pterin \[iii\], 6,7-dimethylpterin \[6,7-diMePterin, iv\], xanthopterin \[v\], pterin-6-carboxylic acid \[vi\], 6-hydroxymethylpterin \[6-OHMePterin, vii\], [l]{.smallcaps}-monapterin \[viii\], tetrahydrobiopterin \[ix\]). (b) Human PBMCs were stained with CD3- and CD161-specific mAbs and human tetrameric MR1--5-OP-RU, MR1-6-FP, or MR1--Ac-6-FP, respectively. Live, CD3^+^ cells were considered for CD161 (x axis) and tetramer staining (y axis), displaying dot plots and percentages of cells within boxed regions. Displayed are the results of three representative of 6 healthy blood donors tested. These experiments were performed twice using two independent batches of tetramer and yielding similar results. (c) MR1 expression levels on C1R.MR1 cells upon incubation with 6-FP, Ac-6-FP, 6,7-dimethylpterin, 6-hydroxymethylpterin, and 5-OP-RU added in indicated doses and for indicated time spans. Cells were stained with anti-MR1 mAb 26.5. Data shows MFI fold of background of MR1 expression levels, mean ± SEM of three independent experiments done in triplicates. These experiments were performed three times, yielding similar results and a representative experiment is shown. (d) Comparison of MR1 expression levels on C1R and C1R.MR1 cells upon incubation with 10 µM 6-FP or Ac-6-FP, or without ligand (media), for different time periods. Cells were stained with anti-MR1 mAb 26.5. Data shows untransformed geometric MFI (gMFI) of MR1 expression levels for each time point. Mean ± SEM of triplicates. These experiments were performed twice, yielding similar results and a representative experiment is shown.](JEM_20140484R_Fig1){#fig1}

![**MAIT cell inhibitory ligands and MR1 stability.** (a) Inhibition of Jurkat.MAIT (original WT, clone A-F7) cell activation by 6-FP or Ac-6-FP. 6-FP, Ac-6-FP (or controls -- 6,7-diMePterin or no ligand) were added to C1R.MR1 cells at the indicated concentrations for 1 h before addition of Jurkat.MAIT cells and 0.02 µM synthetic rRL-6-CH~2~OH. Data shows MFI of CD69 expression levels for gated Jurkat.MAIT cells. Mean ± SEM of triplicates. These experiments were performed twice, yielding similar results and a representative experiment is shown. (b) Inhibition of Jurkat76.MAIT (original WT TCR, clone A-F7) cell activation by 6-FP or Ac-6-FP. 6-FP, Ac-6-FP (or controls, PBS or no ligand) were added to C1R.MR1 cells at the indicated concentrations and co-incubated with Jurkat76.MAIT cells and 0.02 µM synthetic rRL-6-CH~2~OH. Data shows emission at 492 nm correlating with IL-2 production. These experiments were performed three times, showing mean ± SD. (c) Thermostability of soluble MR1-ligand by fluorescence-based thermal shift assay. Shown is baseline-corrected, normalized emission at 610 nm plotted against temperature. Mean ± SEM of triplicate samples, and nonlinear curve-fits. The half maximum melt point (Tm50) is indicated as a dashed line. Displayed is a representative of three independent experiments yielding similar results. The table summarizes the data of three independent experiments, each in triplicate.](JEM_20140484R_Fig2){#fig2}

MAIT TCR-MR1--Ac-6-FP interaction
---------------------------------

To understand the impact of the Ac-6-FP ligand, we expressed and refolded the TRBV6-1^+^ MAIT TCR (original WT; clone A-F7; [@bib53]), added it to refolded MR1--Ac-6-FP, crystallized the ternary complex, and solved its structure to 2.0 Å resolution to an *R~fac~* and *R~free~* of 18.0 and 22.0%, respectively ([Table S1](http://www.jem.org/cgi/content/full/jem.20140484/DC1){#supp1}). The electron density at the MAIT TCR-MR1-Ag interface, and for the ligand itself, was unambiguous ([Fig. 3 a](#fig3){ref-type="fig"}), thereby permitting a direct comparison to the corresponding MAIT TCR-MR1-6-FP structure.

![**MAIT TCR recognition of MR1--Ac-6-FP.** (a) Electron density of Ac-6-FP in omit and final 2Fo-Fc maps of the ternary complex MR1--Ac-6-FP-MAIT original WT (clone A-F7) TCR. Electron density in mesh format, the ligand in ball and stick, MR1 in ribbon representation in white, a Fo-Fc omit map contoured at 3σ (green). (b--d) Structural basis for Ac-6-FP recognition by MR1 and original WT (clone A-F7) MAIT TCR compared with the previously published MR1-6-FP original WT (clone A-F7) MAIT TCR structure (PDB accession no. [4L4T](4L4T)). (b) Superposition of Ac-6-FP and 6-FP and MR1 induced conformational changes. (c) CDR3β conformational changes induced by Ac-6-FP. (d) Contacts between Ac-6-FP and Tyr95α from the CDR3α loop. MR1-6-FP residues are shown in white, pale yellow, and pale orange for the CDR3α and CDR3β loops, respectively, and the 6-FP ligand is shown in cyan. Equivalent residues from the MR1--Ac-6-FP shown in slate, yellow, and orange for the CDR3α and CDR3β loops, respectively and Ac-6-FP in green with contacts between TCR and Ac-6-FP indicated by dashed lines.](JEM_20140484_Fig3){#fig3}

The Ac-6-FP ligand was bound within the MR1 aromatic cradle in the same orientation to that observed with 6-FP, thereby indicating that the inhibitory property of Ac-6-FP was not attributable to differences manifested by altered Ac-6-FP docking within MR1 ([Fig. 3 b](#fig3){ref-type="fig"}). As such, the formyl group of Ac-6-FP formed a Schiff base with Lys43, whereas the pterin ring was sandwiched between Tyr7, Tyr62, Trp69, and Trp156 ([Fig. 3 b](#fig3){ref-type="fig"}). The acetyl moiety formed van der Waals (vdw) interactions with Tyr152, Trp156, and Ile96, with the carbonyl moiety hydrogen bonding to Arg94, which is located at the base of the cleft ([Fig. 3 b](#fig3){ref-type="fig"}). Although the overall conformation of the Ag-binding cleft of MR1 was not appreciably altered in accommodating Ac-6-FP when compared with 6-FP (root mean square deviation (RMSD) of 0.23 Å between MR1-6-FP and MR1--Ac-6-FP over Cα atoms within the α~1~ and α~2~ domains), the presence of the additional moiety did cause conformational changes within the vicinity of the MR1-binding pocket. Namely, to accommodate the acetyl group, Trp69 was repositioned slightly (0.9 Å displacement of Nε1), Tyr152 was moved away (1.1 Å displacement of OH), and the buried residue, Gln153, was repositioned (2.6 Å displacement of Cδ) such that its side chain was orientated away from the binding pocket ([Fig. 3, c and d](#fig3){ref-type="fig"}). This reorientation of Gln153 caused an altered conformation of Glu149 (2.2 Å displacement of Cδ; [Fig. 3 c](#fig3){ref-type="fig"}), a surface-exposed MR1 residue that contacts the MAIT TCR (discussed below). Thus, subtle plasticity within the MR1-Ag--binding cleft allowed for ready accommodation of the acetyl group, with these additional contacts correlating with 8°C increase in the stability of MR1--Ac-6-FP in comparison to MR1-6-FP ([Fig. 1 c](#fig1){ref-type="fig"}). Moreover, these conformational changes affected the conformation of buried residues within the MR1-binding pocket that were transmitted to the MAIT TCR-MR1 contact zone.

The TRBV6-1^+^ MAIT TCR docked onto MR1-6-FP and MR1--Ac-6-FP (RMSD 0.25 Å over all Cα atoms and buried surface area \[BSA\] of 1,100 and 1,210 Å^2^, respectively) in a similar manner. Namely, the MAIT TCR docked orthogonally and centrally over the MR1-Ag--binding cleft, where Tyr95α of the TRAJ33 chain contacted the α~1~ and α~2~ helices of MR1 ([Fig. 3 d](#fig3){ref-type="fig"}), whereas the germline-encoded TRBV6-1 region contacted the α~1~ helix of MR1 only (not depicted). Interestingly, although the CDR3β loop was of identical sequence within these ternary complexes, their respective conformations were different, and this was attributable to Ac-6-FP induced conformational changes ([Fig. 3 c](#fig3){ref-type="fig"}). The CDR3β loop, which made an extensive interface with MR1--Ac-6-FP (BSA 24%), bridged the α~1~ and α~2~ helices of MR1 and was directly positioned over the Ag-binding pocket ([Fig. 3 c](#fig3){ref-type="fig"}). The Ac-6-FP--induced reorientation of Glu149 caused a marked remolding of a major region of the CDR3β loop so as to prevent the electrostatic repulsion of the remodeled Glu149 with Glu99β, which swung down (6.3 Å displacement of Cδ) to slot in between Trp69 and Tyr152 of MR1 ([Fig. 3 c](#fig3){ref-type="fig"}). Notably, the remodeling of Glu99β also resulted in a subtle, albeit important conformational change within the CDR3α loop. Namely, Glu99β "pulled" Tyr95α toward the ligand, enabling it, together with Glu99β from the CDR3β loop backbone, to form direct interactions with the nonstimulatory ligand ([Fig. 3, c and d](#fig3){ref-type="fig"}). These direct contacts with the Ac-6-FP are in contrast to the TRBV6-1^+^ MAIT TCR-MR1-6-FP ternary complex in which no direct contacts were observed between 6-FP and the TCR ([Fig. 3 d](#fig3){ref-type="fig"}). Thus, an MR1-restricted ligand can cause conformational changes to the MR1-binding cleft that are transmitted to the MAIT TCR, which subsequently leads to the hypervariable CDR3β loop making direct contacts with the Ag itself.

Impact of CDR3β variability on MAIT TCR recognition
---------------------------------------------------

Given that the CDR3β loop played a prominent and central role in interacting with MR1, and the conformation of the CDR3β loop could be altered indirectly in an Ag-dependent manner, we asked whether CDR3β loop hypervariability could impact on MAIT TCR-MR1-Ag recognition. To establish this, we selected six TRBV6-1^+^ MAIT TCRs, termed B-B10, B-F3-C1, B-G8, B-C10, C-C10, and C-A11, from published sequence data ([@bib53]) and the original WT TCR ([@bib53]; clone A-F7; described previously \[[@bib45]\]). Although exhibiting some minor differences in the N-region usage at the TRAV1-2-TRAJ33 junctional boundaries, the TCRs principally differed in their CDR3β composition ([Table 1](#tbl1){ref-type="table"}). These 7 MAIT TCRs were chosen because they had limited sequence identity within the CDR3β loops and differed in sequence length (11--13 aa), thereby permitting a broad perspective on CDR3β hypervariability on MAIT TCR recognition.

###### 

MAIT TCR usage and sequences

  TCR (name)   TRAJ   CDR3α                      TRBJ   TRBV   CDR1β            CDR2β             CDR3β
  ------------ ------ -------------------------- ------ ------ ---------------- ----------------- -------------------------------
  WT (A-F7)    33     ^89^AVK*DSNYQLI*^98^       2-2    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSVWTGEG*SGELF*^105^
  B-B10        33     ^89^AGM*DSNYQLI*^98^       1-5    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASTLGQEG*QPQH*^103^
  B-F3-C1      33     ^89^ASI*DSNYQLI*^98^       2-2    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSETDP*NTGELF*^104^
  B-G8         33     ^89^AAM*DSNYQLI*^98^       2-2    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSGG*DSGELF*^102^
  B-C10        33     ^89^AAE*DSNYQLI*^98^       2-6    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSYEV*SGANVLT*^104^
  C-C10        33     ^89^AVV*DSNYQLI*^98^       2-3    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSPPGG*TDTQ\*Y*^103^
  C-A11        33     ^89^AVR*DSNYQLI*^98^       1-3    6-1    ^27^MNHNS^31^    ^49^SASEGT^54^    ^92^ASSAAVEG*GNTIY*^104^
  \#1          12     ^89^AV*MDSSYKLI*^98^       2-1    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92ASSR**GD***YNEQF*102^
  \#2          12     ^89^AV*MDSSYKLI*^98^       2-1    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92ASSASGGAYNEQF104^
  \#3          12     ^89^AV*MDSSYKLI*^98^       2-3    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92ASS**P**GTSGGA*DTQY*105^
  \#4          20     ^89^AVR**DG***DYKLS*^98^   2-2    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92ASS**A**G**AS***TGELF*103^
  \#5          33     ^89^A**VS***DSNYQLI*^98^   2-2    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92ASSDS**G**GG*TGELF*104^
  \#6          33     ^89^AVM*DSNYQLI*^98^       2-1    6-4    ^27^MRHNA^31^    ^49^SNTAGT^54^    ^92^ASS**G**GT*NNEQF*^102^
  C-F7         33     ^89^AFM*DSNYQLI*^98^       2-1    20     ^27^DFQATT^32^   ^50^SNEGSKA^56^   ^95^SARTSGDFG*EQF*^107^

J segments as part of the CDR regions are shown in italics; N regions (known for sequences reported here (MAIT \#1-5) or previously (MAIT \#6; [@bib45]) are shown in bold. Sequence numbering is indicated. \*, Q in TRBJ2-3 but R in [@bib53].

The seven TRBV6-1^+^ MAIT TCRs were expressed, refolded and, as judged by chromatographic profiles, assessed to be fully folded. Initially, we undertook surface plasmon resonance (SPR)--based studies to measure the binding affinity against MR1--5-OP-RU and MR1--Ac-6-FP ([Table 2](#tbl2){ref-type="table"} and [Fig. 4, a--k](#fig4){ref-type="fig"}). The A-F7 WT K~deq~ for MR1--5-OP-RU was ∼2.0 µM, consistent with previous measurements ([@bib40]). The K~deq~ values for the remaining six TRBV6-1^+^ TCRs toward MR1--5-OP-RU were mostly similar ([Table 2](#tbl2){ref-type="table"}), thereby providing insight into why MR1 tetramers of this ligand effectively stain all MAIT cells ([@bib46]; [@bib6]). Nevertheless, some MAIT TCRs (e.g., B-F3-C1) bound more weakly (approximate K~deq~ = 9.1 µM) in comparison to the A-F7 WT value, whereas the B-C10 TCR showed moderately improved binding (approximate K~deq~ = 0.5 µM) to the MR1--5-OP-RU complex ([Table 2](#tbl2){ref-type="table"}). Interestingly, great variation in relative binding affinities was observed against the MR1--Ac-6-FP complex ([Fig. 4 a](#fig4){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). For example, the B-C10 TCR showed a marked preference for MR1--Ac-6-FP (approximate K~deq~ = 35.4 µM) in comparison to the other TRBV6-1^+^ TCRs (K~deq~ \> 200 µM). Accordingly, the CDR3β loop can modulate the affinity toward MR1-restricted ligands. A MAIT TCR with a high affinity for MR1--Ac-6-FP seems rare, however, as we did not observe MR1--Ac-6-FP tetramer^+^ PBMCs ([Fig. 1 b](#fig1){ref-type="fig"}).

###### 

Summary of SPR affinities and MAIT cell activation status

  MAIT TCR             TRAJ   TRBV   K~deq~ (μM), mean duplicate MR1--5-OP-RU   Activation by MR1--5-OP-RU            K~deq~ (μM), mean duplicate Ac-6-FP
  -------------------- ------ ------ ------------------------------------------ ------------------------------------- -------------------------------------
  Original WT (A-F7)   33     6-1    2.0 ± 0.6                                  \+                                    \>200
  B-B10                33     6-1    4.2 ± 0. 6                                 ND                                    \>200
  B-C10                33     6-1    0.5 ± 0.1                                  ND                                    35.4 ± 3.0
  C-A11                33     6-1    4.2 ± 0. 5                                 ND                                    \>200
  C-C10                33     6-1    2.2 ± 0.3                                  ND                                    \>200
  B-G8                 33     6-1    1.4 ± 0.2                                  \+                                    \>200
  B-F3-C1              33     6-1    9.1 ± 1.0                                  \+                                    \>200
  \#1                  12     6-4    1.5 ± 0.1                                  \+                                    \>200
  \#2                  12     6-4    2.2 ± 0.2                                  \+                                    \>200
  \#3                  12     6-4    1.9 ± 0.2                                  \+                                    \>200
  \#1 Y95F             12     6-4    35 ± 2                                     \-                                    \>200
  \#2 Y95F             12     6-4    20 ± 1                                     \-                                    \>200
  \#3 Y95F             12     6-4    33 ± 2                                     \-                                    \>200
  \#4                  20     6-4    2.4 ± 0.4                                  \+                                    \>200
  \#6                  33     6-4    2.7 ± 0.7                                  \+[a](#tblfn1){ref-type="table-fn"}   N/D
  C-F7                 33     20     1.0 ± 0.3                                  \+[a](#tblfn1){ref-type="table-fn"}   N/D

5-OP-RU presented by C1R.MR1 incubated with MAIT cell--activating bacteria ([@bib45]) or rRL-6-CH~2~OH ([@bib40]).

![**MAIT TCR binding affinity and activation.** (a) Relative binding of MAIT TCRs original WT (clone A-F7), B-B10, B-C10, C-A11, C-C10, B-G8, and B-F3-C1 against MR1--Ac-6-FP determined by SPR at 100 µM TCR. (b--k) Equilibrium binding curves for MAIT TCRs. (b) original WT (TRBV6-1, clone A-F7), (c) B-B10, (d) B-C10, (e) C-A11, (f) C-C10, (g) B-G8, (h) B-F3-C1, (i) \#6 (TRBV6-4/TRAJ33), (j) C-F7 (TRBV20), and (k) \#4 (TRAJ20) against MR1--5-OP-RU determined by SPR. Data are representative of the mean response for each TCR concentration and SEM in duplicate (*n* = 2). Dose response to synthetic rRL-6-CH~2~OH (l) or 5-A-RU (m) preincubated with C1R.MR1 cells by TRAV1-2-TRAJ33-TRBV6-1 MAIT TCR^+^ SKW3.B-F3-C1, SKW3.B-G8, and SKW3.original WT (A-F7) or control TCR^+^ SKW3.LC13 cells. Data shows mean ± SEM fold of background MFI of CD69 expression for gated SKW3.TCR cells from 1 experiment (triplicate samples). These experiments were performed twice, yielding similar results.](JEM_20140484_Fig4){#fig4}

To establish whether the differences in affinity for MR1--5-OP-RU between the B-F3-C1 MAIT TCR and a high-affinity MAIT TCR (B-G8) impacted on functional outcome, we transduced the B-F3-C1 and B-G8 MAIT TCRs into the SKW3 T cell line (SKW3.B-F3-C1 and SKW3.B-G8). We then assessed their ability to be activated by synthetic rRL-6-CH~2~OH and 5-A-RU in the presence of C1R.MR1 cells and compared activation to the previously transduced SKW3.MAIT TCR (WT, clone A-F7; [Fig. 4, l and m](#fig4){ref-type="fig"}). Notably, the SKW3.B-F3-C1 showed reduced activation by synthetic rRL-6-CH~2~OH and 5-A-RU when these ligands were not used at saturating concentrations, thereby providing further supporting evidence for the CDR3β loop fine-tuning MAIT TCR reactivity.

Next, we sought a structural basis for the observed effects of CDR3β impacting on MAIT TCR-MR1-Ag recognition. To establish this, we determined the structures of the B-B10, B-F3-C1, B-G8, B-C10, C-C10, and C-A11 MAIT TCRs in complex with MR1--Ac-6-FP and compared them to the original WT (clone A-F7) MAIT TCR MR1--Ac-6-FP ternary complex (Table S1 and [Fig. 5, a--g](#fig5){ref-type="fig"}). All seven TRBV6-1^+^ MAIT TCRs sat similarly onto MR1--Ac-6-FP, thereby indicating that the variations within the CDR3β loop do not impact on MAIT TCR-MR1 docking. Moreover, with the exception of the CDR3β loop-mediated contacts, the majority of the MAIT TCR-MR1 interatomic contacts did not alter appreciably, thereby indicating that variations within the CDR3β loop are not transferrable to the invariant MAIT TCR α chain (with the exception of Tyr95α, discussed below). While the CDR3β loops were similarly disposed atop MR1--Ac-6-FP, the extent of contacts varied between the seven TRBV6-1^+^ MAIT TCRs (BSA values ranging from 15 to 24%), with the CDR3β loop of the original WT (clone A-F7) TCR contributing greatest to the interface and the C-C10 and B-G8 TCRs contributing the least ([Figs. 5, a--g](#fig5){ref-type="fig"}). The CDR3β loops that are relatively rich in glycine residues result in a reduced number of CDR3β-MR1 contacts, while the B-C10 and the A-F7 WT MAIT TCR possess an aromatic residue (Tyr and Trp, respectively, [Figs. 5, a and c](#fig5){ref-type="fig"}) that made conserved interactions with MR1. Further, although there is little/no sequence identity between the CDR3β loops, a negatively charged residue (Asp/Glu) within this loop ([Table 1](#tbl1){ref-type="table"}) converged to a similar position at the interface in four of the seven MAIT TCRs, with the Asp/Glu residue neighboring Tyr95α from the CDR3α loop.

![**Differential CDR3β usage and MAIT TCR-MR1-Ag recognition.** Structural representation of the MR1 surface in white with Ac-6-FP bound, shown in green. MAIT TCR CDR3β loops for the 7 structures are indicated for (a) original WT (TRBV6-1, clone A-F7) in orange, (b) B-B10 in green, (c) C-A11 in purple, (d) B-C10 in cyan, (e) B-G8 in salmon, (f) B-F3-C1 in magenta, and (g) C-C10 in slate. Contacting residues between MR1 and the CDR3β loops are shown in stick representation with the contact surface on MR1 shown according to the MR1 element type: carbon, orange; nitrogen, blue; oxygen, red; and sulfur, yellow. CDR boundaries are listed in [Table 1](#tbl1){ref-type="table"}.](JEM_20140484_Fig5){#fig5}

In all the MAIT TCR-MR1-Ac-6-FP ternary complexes, the additional acetyl moiety caused Gln153 to swing away, which subsequently displaced Tyr152, which caused an altered position of Tyr95α from the CDR3α loop such that it now directly contacts the Ac-6-FP antigen ([Fig. 3 d](#fig3){ref-type="fig"} and not depicted). Thus, the ability of Ac-6-FP to contact the MAIT TCR appears to be an intrinsic feature of the ligand itself and independent of CDR3β sequence variation. Interestingly, the CDR3β loop was also observed to directly contact the Ag, with the acidic residue in the original WT (A-F7), B-B10 and C-A11 MAIT TCRs ([Figs. 5, a--c](#fig5){ref-type="fig"}) directly interacting with the acetyl moiety of Ac-6-FP. However, direct CDR3β--Ag interactions do not necessarily correlate with improved binding affinities for this ligand, as the B-C10 MAIT TCR was observed to have the highest affinity for the MR1-Ac-6-FP complex, indicating that other factors, such as CDR3β flexibility can play an important role in the energetics of the MAIT TCR-MR1-Ag interaction.

As the CDR3β loop can differently interact with MR1--Ac-6-FP, we next asked whether this loop would show altered flexibility in binding a different ligand, namely MR1--5-OP-RU. Accordingly, we determined the structures of the B-B10, B-F3-C1, C-C10, and C-A11 MAIT TCRs in complex with MR1--5-OP-RU ([Table S2](http://www.jem.org/cgi/content/full/jem.20140484/DC1){#supp2}). The CDR3β loops of the B-B10 and B-F3-C1 TCRs did not alter significantly between the MR1--Ac-6-FP and MR1--5-OP-RU complexes, regardless of whether the CDR3β loop directly contacted the Ag or not (unpublished data). However, the presence of the additional ribityl moiety caused moderate and marked conformational changes within the CDR3β loop of the C-A11 and C-C10 MAIT TCRs, respectively ([Fig. 6, a and b](#fig6){ref-type="fig"}). Regarding the C-A11 MAIT TCR, the ribityl moiety, whereas maintaining the hydrogen bond with Glu98β nevertheless caused a reorientation of the Glu98β side chain to form a direct H-bond to Trp69 of MR1 ([Fig. 6 a](#fig6){ref-type="fig"}). The repositioning of Glu98β (2.0 Å displacement of Oε2) subsequently resulted in a remodeling of the main chain of the CDR3β loop (RMSD 0.43 Å over Cα atoms). Interestingly, although the CDR3β loop of the C-C10 TCR did not directly contact Ac-6-FP, within the C-C10 TCR-MR1--5-OP-RU ternary complex, this loop was drawn toward the ligand (6.5 Å displacement of Gly97 O), implying a greater degree of flexibility in the C-C10 CDR3β loop ([Fig. 6 b](#fig6){ref-type="fig"}). The movement of the CDR3β loop enabled its main chain to directly contact the ribityl group of 5-OP-RU through Gly97, which itself exhibited some flexibility in that it reoriented its aliphatic moiety (not shown) to enable favorable contacts with the CDR3β loop ([Fig. 6 b](#fig6){ref-type="fig"}). Thus, our data demonstrate that the flexible CDR3β loop of the MAIT TCR can fine-tune its interactions and responsiveness to MR1 in an Ag-dependent manner.

![**Impact of different Ags on MAIT TCR-MR1-Ag recognition.** Structural differences between the ternary complexes of MR1--Ac-6-FP-MAIT TCR (MR1: white, Ac-6-FP: green, MAIT TCR: cyan) and MR1--5-OP-RU-MAIT TCR (MR1: slate, 5-OP-RU: yellow, MAIT TCR: orange). Remodeling of the (a) C-A11 and (b) C-C10 CDR3β loop between Ac-6-FP and 5-OP-RU complexes, with hydrogen bonds indicated in black dashed lines and vdw contacts in red dashed lines. CDR boundaries are listed in [Table 1](#tbl1){ref-type="table"}.](JEM_20140484_Fig6){#fig6}

Differential Vβ usage
---------------------

In addition to the varied CDR3β usage, the MAIT TCR repertoire is characterized by differential TRBV usage, including the predominant utilization of the TRBV6-1, TRBV6-4, and TRBV20 genes in humans ([@bib46]). Accordingly, we aimed to understand the molecular basis for how the differential TRBV usage can be accommodated while maintaining MR1-Ag recognition. We determined the structures of a TRBV6-4 (clone described previously; [@bib45]; MAIT TCR \#6) and a TRBV20 TCR derived from published sequence data (clone C-F7; [@bib53]) and described previously ([@bib45]) in complex with MR1--5-OP-RU ([Table S3](http://www.jem.org/cgi/content/full/jem.20140484/DC1){#supp3}) and compared them to the TRBV6-1 ternary complex ([Fig. 7, a--h](#fig7){ref-type="fig"}).

The TRBV6-1 and TRBV6-4 TCRs docked similarly onto MR1--5-OP-RU (RMSD of 0.51 Å over all Cα atoms between the TCR Vα and MR1 α~1~ and α~2~ domains; [Fig. 7 a](#fig7){ref-type="fig"}). The TRBV6-1 and TRBV6-4 chains share 83% sequence identity, with some of these differences located within the CDRβ loops and at the MAIT TCR-MR1 interface ([Table 2](#tbl2){ref-type="table"}). However, the CDR1β loop does not make appreciable contacts with MR1 in either ternary complex, and thus the Asn28β → Arg28β substitution in TRBV6-4 does not impact on MR1-Ag recognition ([Fig. 7, c and d](#fig7){ref-type="fig"}). The TRBV6-4 CDR2β loop shows a more prominent contribution to the BSA at the MR1 interface than TRBV6-1 (BSA of 46 and 26%, respectively), whereas the framework regions retain similar contributions between the two structures (BSA of 19% for both complexes; [Fig. 7, c and d](#fig7){ref-type="fig"}). In contrast, the CDR3β loop showed a larger contribution to BSA for TRBV6-1 than TRBV6-4 (53 to 29%, respectively). The affinities of the TRBV6-1 and TRBV6-4 TCRs toward MR1--5-OP-RU were similar (approximate K~deq~ 2.0 µM and 2.7 µM, respectively; [Table 2](#tbl2){ref-type="table"}). Thus, the TRBV6-4 TCR compensates for the lower contribution of the CDR3β loop to the interface BSA by increasing the relative contribution of CDR2β, to achieve a similar docking mode; nevertheless, the overall BSA was lower for TRBV6-4 than TRBV6-1 (1050 Å^2^ and 1160 Å^2^, respectively).

![**TRBV usage and MAIT TCR-MR1-Ag recognition.** Comparison of the MR1--5-OP-RU- MAIT TCR C-F7 (TRBV20), original WT (TRBV6-1, clone A-F7) and \#6 (TRBV6-4) complex variable domains and CDRβ loops in magenta, green and cyan, respectively. (a) Overlay of the CDR loops from the three complexes on the MR1--5-OP-RU groove. (b) Comparison of relative angles for the Vβ-domains of original WT (TRBV6-1, clone A-F7) and C-F7 (TRBV20) MAIT TCR structures. Footprints of the MAIT TCRs on the MR-5-OP-RU surface for (c) original WT (TRBV6-1, clone A-F7), (d) \#6 (TRBV6-4), and (e) C-F7 (TRBV20). Contacting residues between MR1 and the (f) original WT (TRBV6-1, clone A-F7), (g) \#6 (TRBV6-4), and (h) C-F7 (TRBV20) CDR2β loops shown in stick representation with the contact surface on MR1 colored according to the MR1 element type: carbon, orange; nitrogen, blue; oxygen, red. CDR boundaries are listed in [Table 1](#tbl1){ref-type="table"}.](JEM_20140484_Fig7){#fig7}

Although the overall docking mode between the TRBV6-1 and TRBV20^+^ TCRs onto MR1--5-OP-RU was similar (RMSD 0.79 Å over all Cα atoms between the TCR Vα and MR1 α~1~ and α~2~ domains), greater variation in the interatomic contacts were observed due to the lower sequence identity between the respective TCRβ chains (35% sequence identity between Vβ domains; [Table 1](#tbl1){ref-type="table"} and [Fig. 7, c and e](#fig7){ref-type="fig"}). Whereas the TCR α-chain of the TRBV20^+^ MAIT \#4 TCR was situated very similarly atop MR1 when compared with the TRBV6-1^+^ original WT (A-F7) MAIT TCR, the TRBV20 β-chain was juxtaposed differently to that of the TRBV6-1 β-chain, resulting in a 17-degree rotation away from the α1 helix of MR1 ([Fig. 7 b](#fig7){ref-type="fig"}). This difference can be attributed to differing Vα-Vβ packing as well as differing Vβ-MR1 contacts. The BSA contribution of the TRBV20 CDR1β loop was marginally higher than the TRBV6-1 complex (4 and 1%, respectively; [Fig. 7 e](#fig7){ref-type="fig"}). Conversely, TRBV20 framework regions had reduced contributions compared with that of the TRBV6-1 and TRBV6-4 TCRs (BSA of 4, 9 and 8%, respectively; [Fig. 7 e](#fig7){ref-type="fig"}). This was principally due to the TRBV20 lacking Tyr48β (equivalent residue Thr49β; [Fig. 7, f and g](#fig7){ref-type="fig"}), which had the effect of lifting the β-chain away from the MR1 interface. Although the CDR2β loop was devoid of any large residues, thereby reducing the extent of MR1-mediated contacts via this loop, the relative contribution of the CDR2β was similar to TRBV6-1 (10 and 13%, respectively). In addition the relative contribution of the CDR3β to the BSA was similar between TRBV20 and TRBV6-1 (22% and 25%, respectively). Despite this, the overall contact area was decreased in TRBV20 (1070 Å^2^). Accordingly, the TRBV20 chain appeared nonideally disposed to interact with MR1, akin to TRBV6-4. However, in the TRBV20 ternary complex the CDR3β loop played a major role in interacting the MR1--5-OP-RU akin to TRBV6-1 (BSA of 22 and 25%, respectively), thereby structurally compensating for the reduced interactions from the germline encoded regions of the TCR β-chain. Despite the differences in contact area between the complexes the K~deq~, determined by SPR ([Table 2](#tbl2){ref-type="table"}), for MR1--5-OP-RU was comparable for each TCR (∼2.0, 2.7, and 1.0 µM for TRBV6-1 \[original WT, clone A-F7\], TRBV6-4 \[\#6\], and TRBV20 \[\#4\], respectively). This indicates how the MAIT TCR can readily tolerate some variations within the germline-encoded regions of the TCR β-chain.

Atypical TRAJ gene usage
------------------------

Although the invariant MAIT TCR α-chain is characterized by TRAJ33 gene usage, we recently demonstrated that the TCR α-chain could also consist of TRAV1-2 joined with the TRAJ20 or TRAJ12 gene segments ([@bib46]). Although the sequences differ between the TRAJ33, TRAJ12 and TRAJ20 regions, Tyr95α was conserved ([Table 1](#tbl1){ref-type="table"}), thereby suggesting a conserved functional role in mediating contacts with the Ag. To formally establish this, we transduced genes encoding wild-type or mutant Y95F TRAJ20^+^ (\#4) and three TRAJ12^+^, TRBV6-4^+^ MAIT TCRs (\#1--3) differing in CDR3β into SKW3 cells, and compared their activation to that of TRAJ33^+^ MAIT TCR-transduced SKW3 cells (all these TCRs were obtained from single cell sorted PBMCs reactive with MR1-Ag tetramer ([@bib46]; [Fig. 8 a](#fig8){ref-type="fig"}). SKW3 cell lines expressing TRAJ33^+^ (\#5), TRAJ20^+^ (\#4) and TRAJ12^+^ (\#1--3) MAIT TCRs responded equivalently to the activating ligand containing synthetic rRL-6CH~2~OH in the presence of C1R.MR1 cells, and moreover, activation of all the mutant Y95F SKW3 cell lines ([Fig. 8 b](#fig8){ref-type="fig"}) was impaired, thereby indicating a commonality in function between the TRAJ12, TRAJ20, and TRAJ33 MAIT TCRs.

![**TRAJ usage and MAIT TCR recognition.** (a) Dose response to synthetic rRL-6-CH~2~OH preincubated with C1R.MR1 cells by WT (a) or mutant Y95F (b) TRAV1-2-TRBV6-4 TRAJ12^+^, TRAJ20^+^, and TRA33^+^ SKW3.MAIT. Data shows mean ± SEM fold of background MFI of CD69 expression for gated SKW3.TCR cells from one experiment (triplicate samples). These experiments were performed twice yielding similar results. Comparison of the MAIT TCR TRBV6-4 (c) TRAJ20 (\#4) and (d) TRAJ33 (\#6) MR1--5-OP-RU structures with MR1, 5-OP-RU, CDR3α, and CDR3β loops shown in white, yellow, pale yellow, and orange, respectively. (e) Comparison of the positioning of CDR3α loops and Tyr95α for TRAJ20 (\#4) and TRAJ33 (\#6) in slate and pale yellow, respectively. Contacts between CDR3α, CDR3β, and 5-OP-RU are shown with dashed lines in black for hydrogen bonds and red for vdw contacts. CDR boundaries are listed in [Table 1](#tbl1){ref-type="table"}.](JEM_20140484R_Fig8){#fig8}

To directly investigate this, we determined the structure of a TRAJ20^+^ MAIT TCR in complex with MR1--5-OP-RU (Table S3). The TRAJ20^+^ MAIT TCR-MR1-5-OP-RU complex was very similar to the TRAJ33^+^ MAIT TCR-MR1--5-OP-RU complexes with the general positions of the interactions being the same, thereby indicating that divergent TRAJ gene usage does not disrupt the consensus MAIT TCR-MR1 docking mode. Moreover, whereas the sequence differences between TRAJ20 and TRAJ33 gene usage resulted in an altered interaction network within the TCR α/β-chain junctional interface ([Fig. 8 c](#fig8){ref-type="fig"}), Tyr95α adopted a conserved binding mode with the ribityl tail of the 5-OP-RU ligand ([Fig. 8 d](#fig8){ref-type="fig"}). In addition SPR experiments revealed that the dissociation constant for TRAJ20 TCR was comparable to TRAJ33 TCR (∼2.4 and 2.7 µM, respectively; [Table 2](#tbl2){ref-type="table"}). Thus, TRAJ20 and TRAJ12 gene heterogeneity is readily accommodated within the MAIT TCR--MR1 binding axis.

DISCUSSION
==========

MAIT cells, type I NKT cells, and germline-encoded mycolyl lipid-reactive (GEM) cells are T cells that express distinct semiinvariant TCRs, which are restricted to MR1, CD1d, and CD1b, respectively ([@bib48]; [@bib57]). Here, the TCR α-chain is generally fixed, whereas greater repertoire diversity is found within the TCR β-chain. Within the type I NKT cell axis, it is established that the semiinvariant TCR acts like a pattern recognition receptor ([@bib49]). Although the NKT TCR-CD1d docking mode is conserved, variations in TCR β-chain usage can impact on the functional hierarchy of ligand recognition, in a mechanism that involves the CDR2β and CDR3β loops functionally collaborating to enable recognition ([@bib32]). Moreover, NKT TCR β-chains appear to have a penchant for recognizing particular ligands, with the TCR β-chain transmitting conformational changes to the invariant TCR α-chain ([@bib59]). Notably, NKT TCR autoreactivity is mediated via its CDR3β loop ([@bib34]), which directly contacts CD1d, with the extent of autoreactivity being independent on the interactions with the CD1d-restricted Ag ([@bib42]). Further, within the type I NKT system, variations within the TRAV and TRAJ usage is observed, with such differential TCR α-chain usage correlating with differential Ag specificity within the consensus-docking framework ([@bib56]). Thus, although we have a growing understanding of type I NKT TCR recognition of CD1d, it is unclear whether these emerging generalities would be mirrored by MAIT TCR-MR1 recognition, a vitamin B metabolite sensing system. Our data, presented here, provides fundamental insight into the similarities and dissimilarities underpinning NKT TCR and MAIT TCR recognition.

We formally establish that, despite the varied TRAJ, TRBV, and CDR3β usage, the MAIT TCR-MR1-Ag docking mode is conserved, analogous to type I NKT TCRs recognizing CD1d--Ag complexes ([@bib48]). We show how differing TRAJ gene usage converges to similar MAIT TCR-MR1-Ag recognition, with the key CDR3α-encoded residue, Tyr95α, making conserved interactions with the vitamin B metabolite ([@bib45]). Markedly dissimilar to NKT TCR recognition, however, is that the nongermline-encoded CDR3β loop of the MAIT TCR can directly contact the Ag, with the nature of the CDR3β contacts being dynamically and directly modulated by the Ag itself. Moreover, the extent of CDR3β contacts mediated by the MAIT TCR is, on average, much greater than that for NKT TCR recognition, where for the most part the CDR3β loop plays a more peripheral role ([@bib48]). It also appears that, for the ligands tested, the CDR3β loop of the MAIT TCR impacts on MAIT recognition independently of the proximal CDR1β and CDR2β loops. Further, while the CDR3β loop of the NKT TCR can have a huge influence on CD1d autoreactivity ([@bib14]), the impact of the MAIT TCR CDR3β loop appears to play a more subtle fine-tuning role, with the range of affinity values being much more clustered when compared with the effect the NKT TCR's CDR3β loop can have.

In describing a new ligand that competitively inhibits MAIT TCR recognition, Ac-6-FP, we demonstrate that the MR1-binding pocket has sufficient plasticity to accommodate this ligand, and simultaneously show how the ligand itself can markedly affect MR1 stability, which results in greater MR1 cell-surface up-regulation and more potent inhibition. Interestingly, the Ac-6-FP ligand can transmit its effects on MAIT TCR recognition indirectly, by altering the conformation of buried MR1 residues that subsequently affect surface-exposed MR1 residues that directly contact the TCR. In this regard, this is analogous to how buried polymorphic MHC residues can impact on TCR recognition ([@bib1]; [@bib18]) and some CD1d-restricted ligands can impact on F′-pocket dynamics and hence TCR recognition ([@bib35]; [@bib30]; [@bib59]). This raises the possibility that weak agonists could selectively be stimulatory toward a subset of MAIT cells, with a key-determining factor being the CDR3β loop. Accordingly, MAIT TCR heterogeneity, while converging toward a consensus footprint on MR1, can nevertheless fine-tune MAIT TCR recognition.

In MHC-restricted immunity, altered peptide ligands (APLs) can exert markedly differing biological outcomes. Nevertheless, the TCR-MHC-APL docking modes of APL ranging from potent agonists to strong antagonists are very similar ([@bib9]; [@bib8]), thereby indicating that subtle differences at the TCR-pMHC interfaces, and ensuing biophysical parameters of the TCR-pMHC interaction, play a major role in determining the antigenicity of a given peptide ([@bib24]; [@bib10]). The studies reported here are analogous to that of MHC-restricted APLs, in that the MAIT TCR-MR1-Ag docking mode between stimulatory and nonstimulatory MAIT cell antigens are very similar, yet markedly differing biological outcomes are elicited. The affinity of one MAIT TCR toward Ac-6-FP (approximate K~deq~ 34 µM) was shown to be appreciably higher than the remainder of the MAIT TCRs examined (K~deq~ \> 200 µM). Consistent with this, the MR1--Ac-6-FP tetramers have shown that the majority of MAIT cells do not bind with sufficiently high affinity to enable MAIT cell staining. Nevertheless, we are able to observe the MAIT TCR--MR1--Ac-6-FP interaction structurally, in a similar manner to which low-affinity TCR--pMHC interactions have been observed ([@bib60]). Interestingly, the affinity of the nonstimulatory Tyr95αPhe MAIT TCR mutant toward MR1--5-OP-RU was ∼30 µM, thereby indicating that the affinity threshold required for MAIT cell activation is below this value and that an ∼15-fold reduction in affinity can equate to a complete loss of activation. Moreover, a key feature between the stimulatory and nonstimulatory MAIT Ags is the direct contact between Tyr95α of the MAIT TCR and the MAIT Ag. Thus, our findings simultaneously provide insight into the factors that govern MAIT cell antigenicity.

MATERIALS AND METHODS
=====================

### C1R.MR1, Jurkat.MAIT, and SKW3.MAIT cell lines.

C1R APCs expressing MR1 (CIR.MR1) have previously been described ([@bib45]). For the generation of Jurkat.MAIT and SKW3.MAIT cells, full-length TCRα and TCRβ genes were cloned into a self-cleaving 2A peptide-based (MSCV)-IRES-GFP (pMIG) vector ([@bib51]) and stably transduced into TCR-deficient Jurkat clone 76 cells (Jurkat76; [@bib20]), Jurkat RT3-T3.5 cells (Jurkat; American Type Culture Collection no. T1B-153), or SKW3 cells (DSMZ accession code 53) using the retroviral Murine Stem Cell Virus (MSCV) expression system. Transduced cell lines were FACS sorted based on fluorescence of GFP and flow cytometric staining for CD3, which co-expresses on the cell surface with TCR.

### Activation of Jurkat.MAIT and SKW.MAIT cells.

Jurkat or SKW3 cells (10^5^) transduced with genes encoding MAIT TCRα- and TCRβ-chain genes were tested for activation by co-incubation with compounds (synthetic rRL-6-CH~2~OH or 5-A-RU, synthesized as described previously; [@bib6]) and C1R.MR1 cells (10^5^) for 16 h. For inhibition, 6-FP, Ac-6-FP, or control pterins (Schircks Laboratories) were added to C1R.MR1 cells for 1 h before addition of Jurkat.MAIT cells and 0.02 µM synthetic rRL-6-CH~2~OH. Cells were subsequently stained with PE-conjugated anti-CD3 (BD), and APC-conjugated anti-CD69 (BD) mAbs for 30 min on ice, before analysis of CD69 surface expression by flow cytometry. Activation of Jurkat.MAIT or SKW.MAIT cells was measured by an increase in surface CD69 expression.

Jurkat76 cells (10^5^) transduced with genes encoding the WT original (clone A-F7) MAIT TCR α- and β-chain genes were co-incubated with compounds (6-FP, Ac-6-FP; 5-OP-RU; Schircks Laboratories) and C1R.MR1 cells (10^5^) in 200 µl media for 21 h. IL-2 production was measured as a mean of Jurkat76.MAIT activation in ELISA (BD OptEIA kit) using 100 µl of supernatant, frozen/thawed to kill cells. In brief, IL-2 was assayed with biotinylated anti--IL-2 mAb and o-Phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) substrate conversion by HRP-Streptavidin detected at 492 nm emission.

### Detection of up-regulation of MR1 on the cell surface.

C1R.MR1 cells (10^5^) were incubated for 2, 4, or 24 h with compounds. After this, cells were washed and stained with MR1-specific mAb 26.5 on ice for 30 min, followed by PE-conjugated anti--mouse-IgG on ice for 30 min before analysis. For the comparison of C1R and C1R.MR1 expression levels over time, cells (2 × 10^5^) were incubated for 1, 2, 4, 12, or 24 h with 10 µM 6-FP or Ac-6-FP, or no treatment (media alone). Cells were then washed and stained with biotin-conjugated 26.5 mAb, followed by PE-conjugated streptavidin.

### Generation of soluble MR1-ligand, MR1 K43A (empty), C-terminal cysteine-tagged-MR1/ligand, MR1 tetramers, and soluble MAIT TCRs.

Genes were expressed in *E. coli* inclusion bodies, refolded and purified as described previously ([@bib40]). Tetramers were generated as described previously ([@bib6]) and prepared simultaneously.

### Tetramer staining of PBMCs.

PBMCs were isolated from whole blood of healthy donors (authorized by the Australian Red Blood Cross Service Material Supply Agreement with the University of Melbourne) as described previously ([@bib46]). Approximately 1.2 × 10^6^ human PBMCs were stained with live/dead discriminator (Live/Dead Fixable Aqua Dead Cell Stain kit; Invitrogen) PE-labeled, human tetrameric, MR1--5-OP-RU, MR1-6-FP or MR1--Ac-6-FP at 5 µg/ml, anti-CD3-Alexa Fluor 700 (BD), and anti-CD161-PE-Cy7 (BioLegend) mAb for 30 min on ice in the dark. Cells were then washed three times with wash buffer (2% fetal calf serum in PBS) and resuspended in fixing solution (2.1% glucose and 1% paraformaldehyde in PBS). Data were acquired using an LSR Fortessa (BD) and analyzed using FlowJo software.

### Thermostability of soluble MR1 by fluorescence-based thermal shift assay.

Soluble MR1-6-FP, MR1--Ac-6-FP, MR1--5-OP-RU and MR1-K43A (empty) were purified by gel filtration before the assay. To generate MR1-K43A-5-OP-RU (loaded), MR1-K43A was incubated in TBS with a 10 M excess of 5-OP-RU, prepared as described previously ([@bib6]), for 4 h at room temperature in the dark. To separate 5-OP-RU--loaded MR1-K43A from unloaded MR1-K43A, complex of soluble MAIT TCR-MR1-K43A-5-OP-RU was purified by gel filtration. MR1-K43A-5-OP-RU was subsequently separated from MAIT TCR through the addition of excess 12H8 mAb specific for TCR (∼1.1:1.0 molar ratio 12H8 mAb to MAIT TCR in MR1-TCR complex), followed by gel filtration whereby MAIT TCR complexed with 12H8 mAb shifted to earlier elution volume as compared with MR1-K43A-5-OP-RU.

For the fluorescence-based thermal shift assay, triplicate samples consisting of 5 µg of MR1 and 2.5 µg of SYPRO Orange (Sigma-Aldrich) in 20 µl TBS were prepared on ice. Samples were heated from 25 to 95°C at a rate of 1°C/min using a Stratagene Mx3005P Real Time PCR machine. Thermal protein unfolding caused unquenching of SYPRO Orange fluorescent signal, resulting in an increase of fluorescence signal (excitation at 492 nm, emission 610 nm). Emission signal at 610 nm was plotted against temperature and half maximum melt point (Tm50), at which 50% of the protein is unfolded, was determined upon base line correction, normalization, and nonlinear curve fit using the software GraphPad Prism. The experiment was performed three times.

### Surface plasmon resonance.

All surface plasmon resonance (SPR) experiments were conducted in duplicate at 25°C on a BIAcore 3000 instrument using HBS buffer: 10 mM HEPES-HCl (pH 7.4), 150 mM NaCl, and 0.005% surfactant P20 supplied by the manufacturer (GE Healthcare). Biotinylated C-terminal cysteine-tagged-MR1-Ag (generated as described previously e.g., ([@bib40])) were immobilized on a SA-Chip with a surface density of ∼3000-4000 response units (RU). Various concentrations of MAIT TCRs (between 0.2 and 50 µM) were injected over the captured MR1-Ag at 10 µl/min. The final response was calculated by subtracting the response of a biotin-labeled flow cell alone from the TCR-MR1-Ag complex. The equilibrium data were analyzed using GraphPad Prism to determine affinity constants as the result of two independent experiments.

### Crystallization, structure determination and analysis.

Crystals of the soluble MAIT TCR-MR1-Ag complexes were obtained using the hanging drop vapor diffusion method. The MR1-β~2~M-5-OP-RU, MR1-β~2~M-Ac-6-FP and MAIT TCRs were concentrated to between 2--4 mg/ml, mixed in a 1:1 molar ratio, then 0.5 µl added to 0.5 µl of a precipitant solution consisting 0.2 M sodium acetate, 0.1 M bis-tris propane with a pH ranging between 6 and 6.5, and varying concentrations of PEG 3350 between 8--14% wt/vol depending on the complex. Crystals were observed after incubation at 20°C for 24 h in dark conditions. Cryoprotected before diffraction experiments by soaking in the crystallization condition modified with between 10--15% vol/vol glycerol before cooling to 100K. Diffraction images were collected at the Australian Synchrotron MX2 beamline, diffracting in either a *C2*, *P3~1~* (MAIT TCR TRBV20 only) or *P4~1~2~1~2* (MAIT TCR TRAJ20 only) spacegroups. The data were processed using either XDS ([@bib26]) or programs from the CCP4 Suite ([@bib58]). The phase problem was solved by molecular replacement using PHASER ([@bib36]), using MR1 ternary complex (Protein Data Bank accession no. [4L4T](4L4T); [@bib40]) with CDR loops and ligands removed and using the *R~free~* reflection set from the model. The initial solution was refined in Phenix using simulated annealing refinement, with all subsequent refinement steps performed using BUSTER 2.10. Restraints for 5-OP-RU and Ac-6-FP were generated using the Grade Web Server, with model building performed in COOT using MolProbity for validation ([@bib13]). All molecular graphics were made with PyMOL. The buried surface area was calculated with Areaimol ([@bib58]) and RMSD values were calculated using the align function in PyMOL. Within the *C2* crystal form there are two complexes per asymmetric unit, with these two complexes being very similar to each other. In relation to the Ag-binding pocket of the structures reported here and previously ([@bib40]), minor perturbations around the side chains of E149 and Q153 were observed, but this lies within coordinate error. Accordingly, unless explicitly stated, only one complex per asymmetric unit will be discussed in the manuscript.

### Accession information.

The coordinates have been deposited in the Protein Data Bank under the following accession codes: [4PJ5](4PJ5), [4PJ7](4PJ7), [4PJ8](4PJ8), [4PJ9](4PJ9), [4PJA](4PJA), [4PJB](4PJB), [4PJC](4PJC), [4PJD](4PJD), [4PJE](4PJE), [4PJF](4PJF), [4PJG](4PJG), [4PJH](4PJH), [4PJI](4PJI), and [4PJX](4PJX).

### Online supplemental material.

Table S1 shows data collection and refinement statistics for the ternary complexes MR1-Ac-6-FP-MAIT TCR. Table S2 shows data collection and refinement statistics for the ternary complexes MR1-5-OP-RU-MAIT TCR. Table S3 shows data collection and refinement statistics for the ternary complexes MR1-5-OP-RU-MAIT TCR. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20140484/DC1>.
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